|23.73||+0.0600||+0.25%||Vol 1.39M||1Y Perf -36.95%|
|Jan 14th, 2022 16:00 DELAYED|
|- -||-0.13 -0.55%|
|Target Price||52.44||Analyst Rating||Strong Buy 1.06|
|Potential %||120.99||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-82/-85/-87||Value Ranking||★+ 44.81|
|Insiders Value % 3/6/12 mo.||-76/-88/-92||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-77/-89/-92||Income Ranking||— -|
|Price Range Ratio 52W %||7.38||Earnings Rating||Neutral|
|Market Cap||2.81B||Earnings Date||24th Feb 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||24th Feb 2022|
|Estimated EPS Next Report||-0.89|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||821.32K|
|Avg. Monthly Volume||668.00K|
|Avg. Quarterly Volume||753.24K|
Insmed Inc. (NASDAQ: INSM) stock closed at 23.73 per share at the end of the most recent trading day (a 0.25% change compared to the prior day closing price) with a volume of 1.39M shares and market capitalization of 2.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 521 people. Insmed Inc. CEO is William Lewis.
The one-year performance of Insmed Inc. stock is -36.95%, while year-to-date (YTD) performance is -12.89%. INSM stock has a five-year performance of 54.09%. Its 52-week range is between 22 and 45.44, which gives INSM stock a 52-week price range ratio of 7.38%
Insmed Inc. currently has a PE ratio of -6.60, a price-to-book (PB) ratio of 6.04, a price-to-sale (PS) ratio of 22.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -39.58%, a ROC of -41.77% and a ROE of -98.89%. The company’s profit margin is -%, its EBITDA margin is -216.20%, and its revenue ttm is $132.34 Million , which makes it $1.12 revenue per share.
Of the last four earnings reports from Insmed Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Insmed Inc.’s next earnings report date is 24th Feb 2022.
The consensus rating of Wall Street analysts for Insmed Inc. is Strong Buy (1.06), with a target price of $52.44, which is +120.99% compared to the current price. The earnings rating for Insmed Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Insmed Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Insmed Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.75, ATR14 : 1.37, CCI20 : -164.53, Chaikin Money Flow : 0.12, MACD : -1.08, Money Flow Index : 18.14, ROC : -12.82, RSI : 31.83, STOCH (14,3) : 19.19, STOCH RSI : 0.17, UO : 47.63, Williams %R : -80.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Insmed Inc. in the last 12-months were: Christine A. Pellizzari (Option Excercise at a value of $706 878), Christine A. Pellizzari (Sold 65 150 shares of value $2 803 324 ), David R Brennan (Buy at a value of $301 500), John Soriano (Option Excercise at a value of $1 980 116), John Soriano (Sold 86 478 shares of value $3 271 468 ), Martina Flammer (Sold 2 918 shares of value $76 828 ), Michael Smith (Sold 1 543 shares of value $40 962 ), Roger Adsett (Sold 6 044 shares of value $160 355 ), S. Nicole Schaeffer (Option Excercise at a value of $855 327), S. Nicole Schaeffer (Sold 65 040 shares of value $1 953 988 ), Sara Bonstein (Sold 1 154 shares of value $28 977 ), Steinar J. Engelsen (Buy at a value of $529 042), William Lewis (Option Excercise at a value of $2 336 054), William Lewis (Sold 405 178 shares of value $12 016 324 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.